Changes in anti-viral effectiveness of interferon after dose reduction in chronic hepatitis c patients: A case control study

被引：24

作者：

Bekkering F.C. ^{[1
]}

Neumann A.U. ^{[2
]}

Brouwer J.T. ^{[1
]}

Levi-Drummer R.S. ^{[2
]}

Schalm S.W. ^{[1
]}

机构：

[1] Dept. of Hepatology/Gastroenterology, University Hospital Rotterdam, Rotterdam

[2] Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan

来源：

BMC Gastroenterology | / 1卷 / 1期

关键词：

Million Unit; Free Virion; Viral Dynamic; Viral Kinetic; Phase Slope;

D O I：

10.1186/1471-230X-1-14

中图分类号：

学科分类号：

摘要：

Background: High dose interferon induction treatment of hepatitis C viral infection blocks viral production over 95%. Since dose reduction is often performed due to clinical considerations, the effect of dose reduction on hepatitis C virus kinetics was studied. Methods: A new model that allowed longitudinal changes in the parameters of viral dynamics was used in a group of genotype-1 patients (N = 15) with dose reduction from 10 to 3 million units of interferon daily in combination with ribavirin, in comparison to a control group (N = 9) with no dose reduction. Results: Dose reduction gave rise to a complex viral kinetic pattern, which could be only explained by a decrease in interferon effectiveness in blocking virion production. The benefit of the rapid initial viral decline following the high induction dose is lost after dose reduction. In addition, in some patients also the second phase viral decline slope, which is highly predictive of success of treatment, was impaired by the dose reduction resulting in smaller percentage of viral clearance in the dose reduction group. Conclusions: These findings, while explaining the failure of many induction schedules, suggest that for genotype-1 patients induction therapy should be continued till HCVRNA negativity in serum in order to increase the sustained response rate for chronic hepatitis C. © 2001 Bekkering et al; licensee BioMed Central Ltd.

引用

页数：10

共 17 条

[1]

Alter M.J., Epidemiology of hepatitis C, Hepatology, 26, (1997)

[2]

McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., Albrecht J.K., Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C, N. Engl. J. Med., 339, pp. 1485-1492, (1998)

[3]

Lin R., Roach E., Zimmerman M., Strasser S., Farrell G.C., Interferon alfa-2b for chronic hepatitis C: Effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial, J. Hepatol., 23, pp. 487-496, (1995)

[4]

Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C., Albrecht J., Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus, Lancet, 352, pp. 1426-1432, (1998)

[5]

Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., Perelson A.S., Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy, Science, 282, pp. 103-107, (1998)

[6]

Bekkering F.C., Brouwer J.T., Leroux-Roels G., Van Vlierberghe H., Elewaut A., Schalm S.W., Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy, J. Hepatol., 28, pp. 960-964, (1998)

[7]

Zeuzem S., Schmidt J.M., Lee J.H., Ruster B., Roth W.K., Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo, Hepatology, 23, pp. 366-371, (1996)

[8]

Lam N.P., Neumann A.U., Gretch D.R., Wiley T.E., Perelson A.S., Layden T.J., Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa, Hepatology, 26, pp. 226-231, (1997)

[9]

Bekkering F.C., Stalgis C., McHutchison J.G., Brouwer J.T., Perelson A.S., Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model, Hepatology, 33, pp. 419-423, (2001)

[10]

Brouwer J.T., Nevens F., Kleter B., Elewaut A., Adler M., Brenard R., Chamuleau R.A., Michielsen P.P., Pirotte J., Hautekeete M.L., Weber J., Bourgeois N., Hansen B.E., Bronkhorst C.M., ten Kate F.J., Heijtink R.A., Fevery J., Schalm S.W., Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients, J. Hepatol., 28, pp. 951-959, (1998)

← 1 2 →